Network Pharmacology-Based Analysis on the Curative Effect of Kunxian Capsules against Rheumatoid Arthritis. (30th September 2021)

• Record Type: Journal Article
• Authors: Yan, Hong-Xia; Xu, Chun-Fang; Yang, Hong; Wen, Xiao-Ya; Wang, Zhi-Peng; Chen, Yan-Hong; Liu, Jing-Xue; Chen, Wan-Sheng; Gao, Shou-Hong; Tao, Xia
• Other Names: Emran Talha Bin Academic Editor.
• Is Part Of: Evidence-based complementary and alternative medicine. Volume 2021(2021)
• Publication Date: 2021-09-30
• Subjects: Alternative medicine -- Periodicals; 615.505
• DOI: 10.1155/2021/6812374
• Languages: English
• ISSNs: 1741-427X

Abstract

Abstract : Kunxian capsules (KCs), a Chinese patent medicine, have been clinically proven to be effective in the treatment of rheumatoid arthritis (RA). However, the chemical profile of KC remains to be characterized, and the mechanism underlying the protective effect against RA is yet to be elucidated. Here, a network pharmacology-based approach was adopted, integrated with the chemical profiling of KC by UHPLC-Q-TOF/MS. As a result, a total of 67 compounds have been identified from KC extract, among which 43 were authenticated by comparison to the mass spectrum of standard chemicals. ADME behaviors of the chemical constituents of KC were predicted, resulting in 35 putative active ingredients. Through target prediction of both active ingredients of KC and RA and PPI analysis, core targets were screened out, followed by biological process and related pathway enrichment. Then, a TCM-herb-ingredient-target-pathway network was constructed and a multicomponent, multitarget, and multipathway synergistic mechanism was proposed, providing an information basis for further investigation. The active pharmaceutical ingredients included mainly terpenoids (such as triptolide and celastrol), sesquiterpene pyridines (such as wilforgine and wilforine), and flavonoids (such as icariin, epimedin A, B, and C, and 2″-O-rhamnosylicariside II).